{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T10:14:18Z","timestamp":1726481658579},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","immunology.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.iac.2014.04.011","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T22:30:26Z","timestamp":1405031426000},"page":"645-662","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antiviral Drug Allergy"],"prefix":"10.1016","volume":"34","author":[{"given":"Brigitte","family":"Milpied-Homsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen M.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib1","first-page":"42","article-title":"Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system","volume":"8","author":"Vilar","year":"2003","journal-title":"J\u00a0HIV Ther"},{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/ACI.0b013e32825ea68a","article-title":"Drug hypersensitivity in HIV","volume":"7","author":"Phillips","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2014.04.011_bib4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","article-title":"The abacavir hypersensitivity reaction: a review","volume":"24","author":"Clay","year":"2002","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","article-title":"HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz","volume":"22","author":"Vitezica","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib6","first-page":"125","article-title":"Managing adverse effects and complications in completing treatment for hepatitis C virus infection","volume":"20","author":"Sherman","year":"2012","journal-title":"Top Antivir Med"},{"issue":"8","key":"10.1016\/j.iac.2014.04.011_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/1346-8138.12199","article-title":"Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan","volume":"40","author":"Torii","year":"2013","journal-title":"J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2014.04.011_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1345\/aph.1A287","article-title":"Efavirenz-induced skin eruption and successful desensitization","volume":"36","author":"Phillips","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamadermatol.2013.938","article-title":"Telaprevir-related dermatitis","volume":"149","author":"Roujeau","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"9312","key":"10.1016\/j.iac.2014.04.011_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"issue":"9308","key":"10.1016\/j.iac.2014.04.011_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.iac.2014.04.011_bib13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.iac.2014.04.011_bib14","unstructured":"Phillips EB, Sanne I, Lederman M, et\u00a0al. Associations between HLA-DRBA*0102, HLA-B*5801 and hepatotoxicity in patients who initiated nevirapine containing regimens in South Africa. 18th Conference on retroviruses and opportunistic infections. Boston, February 27\u2013March 1, 2011. Paper #949."},{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/cir403","article-title":"Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash","volume":"53","author":"Chantarangsu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.iac.2014.04.011_bib17","first-page":"48","article-title":"HLA-B*35 is associated with nevirapine hypersensitivity in the contemporary western Australian HIV cohort study","volume":"42","author":"Phillips","year":"2010","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.011_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients","volume":"6","author":"Likanonsakul","year":"2009","journal-title":"AIDS Res Ther"},{"issue":"9","key":"10.1016\/j.iac.2014.04.011_bib19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.iac.2014.04.011_bib20","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and Nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iac.2014.04.011_bib22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"issue":"16","key":"10.1016\/j.iac.2014.04.011_bib23","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/00002030-200211080-00017","article-title":"Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir","volume":"16","author":"Phillips","year":"2002","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.iac.2014.04.011_bib24","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib25","first-page":"15","article-title":"Testing for drug hypersensitivity syndromes","volume":"34","author":"Rive","year":"2013","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.iac.2014.04.011_bib27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1034\/j.1398-9995.2002.02161.x","article-title":"Pathogenesis of drug-induced exanthems","volume":"57","author":"Pichler","year":"2002","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2014.04.011_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2125.2010.03764.x","article-title":"Delayed drug hypersensitivity: models of T-cell stimulation","volume":"71","author":"Adam","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01163.x","article-title":"The structural basis of HLA-associated drug hypersensitivity syndromes","volume":"250","author":"Pompeu","year":"2012","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2332\/allergolint.55.17","article-title":"Pharmacological interaction of drugs with immune receptors: the p-i concept","volume":"55","author":"Pichler","year":"2006","journal-title":"Allergol Int"},{"issue":"7404","key":"10.1016\/j.iac.2014.04.011_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.iac.2014.04.011_bib32","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","article-title":"Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity","volume":"26","author":"Norcross","year":"2012","journal-title":"AIDS"},{"issue":"25","key":"10.1016\/j.iac.2014.04.011_bib33","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.iac.2014.04.011_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.iac.2009.04.007","article-title":"The variable clinical picture of drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug","volume":"29","author":"Kano","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.iac.2014.04.011_bib36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1365-2133.2007.08167.x","article-title":"Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome","volume":"157","author":"Tohyama","year":"2007","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2014.04.011_bib37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.iac.2014.04.011_bib38","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2012.02.004","article-title":"Severe cutaneous eruptions on telaprevir","volume":"57","author":"Chen","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bjid.2012.10.010","article-title":"Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions","volume":"17","author":"Teixeira","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.iac.2014.04.011_bib43","unstructured":"Advisory Committee Briefing Document for NDA 201-917 Telaprevir 375 mg tablets In: Members APAC, ed."},{"issue":"5","key":"10.1016\/j.iac.2014.04.011_bib44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jac\/dkn292","article-title":"Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection","volume":"62","author":"Borras-Blasco","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"19","key":"10.1016\/j.iac.2014.04.011_bib45","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2014.04.011_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"issue":"14","key":"10.1016\/j.iac.2014.04.011_bib49","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.iac.2014.04.011_bib50","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s15010-004-4034-8","article-title":"Efavirenz-associated Stevens-Johnson syndrome","volume":"32","author":"Colebunders","year":"2004","journal-title":"Infection"},{"issue":"5\u20136","key":"10.1016\/j.iac.2014.04.011_bib51","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00228-003-0613-3","article-title":"Incidence and risk factors for nevirapine-associated rash","volume":"59","author":"de Maat","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00042560-200109010-00003","article-title":"Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09\/99 study","volume":"28","author":"Knobel","year":"2001","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"18","key":"10.1016\/j.iac.2014.04.011_bib53","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1097\/00002030-200112070-00010","article-title":"Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine","volume":"15","author":"Wit","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/11209110-000000000-00000","article-title":"Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib55","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/QAD.0b013e32835e1554","article-title":"Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies\/ml or less: week 48 phase III analysis","volume":"27","author":"Molina","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1258\/ijsa.2008.008331","article-title":"A\u00a0delayed hypersensitivity reaction to enfuvirtide after rechallenge","volume":"20","author":"Emerson","year":"2009","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.iac.2014.04.011_bib57","unstructured":"Phillips E, Keane N, Blyth C, et\u00a0al. Both HLA Class I restricted CD8+ and Class II restricted CD4+T cells are implicated in the pathogenesis of nevirapine hypersensitivity. In: 51st Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago; 2011."},{"issue":"3","key":"10.1016\/j.iac.2014.04.011_bib58","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11882-013-0418-0","article-title":"Genotyping for severe drug hypersensitivity","volume":"14","author":"Karlin","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"7","key":"10.1016\/j.iac.2014.04.011_bib59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/pgs.10.77","article-title":"Pharmacogenetics of drug hypersensitivity","volume":"11","author":"Phillips","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.iac.2014.04.011_bib60","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/0956462413481528","article-title":"Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome\u2014implications for clinical practice and patient safety","volume":"24","author":"Perry","year":"2013","journal-title":"Int J STD AIDS"},{"issue":"10","key":"10.1016\/j.iac.2014.04.011_bib61","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/00365548.2012.689850","article-title":"Raltegravir-induced DRESS syndrome","volume":"44","author":"Loulergue","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"10.1016\/j.iac.2014.04.011_bib62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D39X26T1QN","article-title":"DRESS syndrome associated with raltegravir","volume":"17","author":"Zhang","year":"2011","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1545109712462454","article-title":"Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals","volume":"12","author":"Babiker","year":"2013","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"issue":"1","key":"10.1016\/j.iac.2014.04.011_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J\u00a0Infect Dis"},{"issue":"23","key":"10.1016\/j.iac.2014.04.011_bib66","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.iac.2014.04.011_bib67","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2014.04.011_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2040622312441496","article-title":"Boceprevir in chronic hepatitis C infection: a perspective review","volume":"3","author":"Ascione","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"10.1016\/j.iac.2014.04.011_bib69","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2013.12.008","article-title":"First case of drug rash eosinophilia and systemic symptoms due to boceprevir","volume":"60","author":"Samain","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib70","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/hep.25574","article-title":"Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash","volume":"55","author":"Dupin","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.iac.2014.04.011_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3810\/pgm.2005.05.1629","article-title":"Recognizing drug allergy. How to differentiate true allergy from other adverse drug reactions","volume":"117","author":"Weiss","year":"2005","journal-title":"Postgrad Med"},{"issue":"9","key":"10.1016\/j.iac.2014.04.011_bib72","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0b013e3282f7cb60","article-title":"A\u00a0review of drug patch testing and implications for HIV clinicians","volume":"22","author":"Shear","year":"2008","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.iac.2014.04.011_bib73","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2169\/internalmedicine.43.533","article-title":"Photosensitive drug eruption induced by efavirenz in a patient with HIV infection","volume":"43","author":"Furue","year":"2004","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.iac.2014.04.011_bib74","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2169\/internalmedicine.43.630","article-title":"The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection","volume":"43","author":"Yoshimoto","year":"2004","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.iac.2014.04.011_bib75","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/00002030-200105250-00029","article-title":"Efavirenz-induced photoallergic dermatitis in HIV","volume":"15","author":"Treudler","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib76","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","article-title":"Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","volume":"20","author":"Pollard","year":"1998","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.iac.2014.04.011_bib77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-200406000-00002","article-title":"Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity","volume":"14","author":"Hughes","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"15","key":"10.1016\/j.iac.2014.04.011_bib78","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/QAD.0b013e3283103ce6","article-title":"The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV","volume":"22","author":"Schackman","year":"2008","journal-title":"AIDS"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T18:45:57Z","timestamp":1649616357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856114000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0889856114000599"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2014.04.011","relation":{},"ISSN":["0889-8561"],"issn-type":[{"type":"print","value":"0889-8561"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Drug Allergy","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2014.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}